Biophan Technologies, Inc.
Company Overview and Update
The Wall Street Analyst Forum – 16th Annual Analyst Conference
March 2, 2005
Michael Weiner, CEO
Biophan Technologies, Inc. (OTCBB: BIPH)
Biophan’s Mission
Enable over $12 billion worth of medical devices shipping annually safe for use with MRI, and imageable. Many are not: Guidewires, catheters, endoscopes, biopsy needles Pacemakers, defibrillators, neurostimulators, drug
pumps (safety issues, also imaging issues), pain control devices
Stents, embolism clips, aneurysm clips, artificial hips, knees, most other orthopedics
Bring other innovations for competitive advantage to biomedical device and pharmaceutical companies.
Biophan Technologies, Inc. (OTCBB: BIPH)
Summary Financial Information
Share Price (02.28.05): $1.55 52-Week High: $1.55 52 Week Low: $0.46 Shares Outstanding: 74 million Float: 58 million Market Cap: $114.7 million Average Daily Volume: 510,454
BIOPHAN (OTC: BIPH)
Biophan Technologies, Inc. (OTCBB: BIPH)
Biophan’s Solutions
MRI Safety: (many products contraindicated) RF filter from Johns Hopkins (heating) Biophan multi-filar wire solution (heating) “Anti-Antenna” lead design (induced voltages)
Image Compatibility Nanomagnetic particle thin film coatings (Nanoset, LLC
and Alfred University) Minimize image artifacts Makes catheters, guidewires, stents, and devices visible
under MRI
Biophan Technologies, Inc. (OTCBB: BIPH)
Management
Stu MacDonald, VP R&D at J&J division, with a 400 person organization
Jeff Helfer, VP Engineering – formerly Dir. Of Engineering at the same J&J division
John Lanzafame, President, Nanolution Division – former President STS Biopolymers, acquired by Angiotech (ANPI)
Robert Wood, VP Finance, Treasured and CFO, CPA in public and private firms
And now Dr. Michael Friebe, and Dr. Andreas Melzer, two well known leaders in MRI technologies
Biophan Technologies, Inc. (OTCBB: BIPH)
Biophan-Europe
Acquired February, 2005, AMRIS (now Biophan Europe) adds enormous additional capability to Biophan
2 Ph.D. level MRI experts, Friebe and Gregor MD, surgeon and inventor, Andreas Melzer, MD Access to latest MRI devices Excellent connections in the MRI community Exciting, patented solutions
Biophan Technologies, Inc. (OTCBB: BIPH)
Core Business
Offering our customers competitive advantage Through proprietary solutions that can gain
marketshare for them FDA approval is pursued by the customer Marketing and distribution of the final device is
theirs We sell high margin components and develop
annuities for our shareholders
Biophan Technologies, Inc. (OTCBB: BIPH)
Relationship With Boston Scientific
Joint development agreement, originally entered into November, 2003
Recently moved to second and third phase, and has expanded to multiple products
One of the companies referred to in recent 10Q Reached agreement on term sheet, working on
final contract phase
MRI Device Imaging
SE coronal image of 3 aluminum wires (1/32”). Wire (3) is uncoated.
1 2 3
Biophan’s thin-film
nanomagnetic particle
coating technology
provides a controllable,
“magnetic” signal
capable of creating an
image of the coated
device.
#3 is uncoated.
Biophan Technologies, Inc. (OTCBB: BIPH)
Making Stents Imageable
Seeing blockage of stents has required an invasive procedure
Stents imageable under MRI would be competitively advantaged
Biophan’s business is competitive advantage for our customers through technology innovation
Nanoset has a coating solution AMRIS, now Biophan-Europe, has a “retrofit” solution Both solutions are PATENTED! Together we “cover the waterfront”
Biophan Technologies, Inc. (OTCBB: BIPH)
Implications
Impact the $5+ billion stent market Help manufacturers make pacemakers,
defibrillators, neurostimulators safe, and imageable – competitive advantage to our licensees
Make guidewires, catheters, endoscopes, biopsy needles safe and image compatible
Opens the field of interventional medicine under MRI (currently only X-Ray/Fluoroscopy)
Biophan Technologies, Inc. (OTCBB: BIPH)
Biothermal Battery
Goal: To provide a long-lived electrical power system for implanted medical devices Powered by body heat differential.
Acquired 51% interest in TE-Bio, which holds an issued U.S. patent for the battery
Batteries are a $500 million market, sell for $100 to $225 each in the pacemaker, defibrillator and drug pump markets
Sold to same customers who need MRI safety
Biophan Technologies, Inc. (OTCBB: BIPH)
Agreement with NASA
Announced on August 17th a deal with NASA Ames Research Center for Nanotechnology to jointly develop the biothermal battery NASA wants technology for their long duration
manned MARS mission for biosensing and miniature therapeutic devices
Biophan gets commercial rights to jointly developed and NASA developed technology
Nanotechnology and materials science advances makes the biothermal battery possible
Biophan Technologies, Inc. (OTCBB: BIPH)
Substrate
Polymer Coating
Nanomagnetic layer
Con
trol
led
Mag
netic
Fie
ldDrug bound to NMP carrier
Con
trol
led
Mag
netic
Fie
ld A
Con
trol
led
Mag
netic
Fie
ld B
Particle type ADrug AParticle type BDrug B
Surface Elution on Demand
Biophan Technologies, Inc. (OTCBB: BIPH)
Reloading Drug Eluting Coatings
Substrate
Polymer Coating
Concentration G
radient
Controlled
Magnetic F
ield
Drug Molecules
Drug bound to NMP carrier
Nanomagnetic layer
Biophan Technologies, Inc. (OTCBB: BIPH)
Guided Drug Delivery
Solid tumor
Apply magnetic field to concentrate particles
Modulate field to release drug from particles
Inject NMPs IV,NMP will circulate through the blood stream
Other options for targeting:1 - Direct injection into tumor site2 - Coating NMP with antibodies to target tumor
Biophan Technologies, Inc. (OTCBB: BIPH)
Other Solution Offerings
MRI Safe Drug Pump (non-magnetic) Nanomagnetic particles for contrast agents
Also used forMRI compatibilityReduce device heatingEnable DRUG DELIVERY CAPABILITIES!
NanoViewtm
MRI Contrast Agents
NanoViewtm
Nano-particulate technology has the potential to
provide a new consumable product capable of
significantly enhancing MR detection sensitivity
(i.e. lowest detectable concentration) and
specificity (i.e. the ability to reliably detect the
desired substance).
Biophan Technologies, Inc. (OTCBB: BIPH)
PROTECTED, PROTECTED!
Technologies covered by 108 U.S. Patents
33 ISSUED 75 pending or allowed
Owned by Biophan or licensed exclusively to Biophan for the medical market
Plus many International patents
Biophan Technologies, Inc. (OTCBB: BIPH)
Goals
Close major deal – underway, at contract phase Close second deal – we have multiple prospects
in the U.S. Europe, and Asia List on major exchange – requires $5 million
capital, we meet all other qualifications, we plan to file as soon as capital in hand
Biophan Technologies, Inc. (OTCBB: BIPH)
Revenue Potential for MRI Safety and Visibility (by example, not a forecast)
Customer Sales
In Billion$ Year3%
(million$ yr)
5%(million$ yr)
1 30 50
2 60 100
3 90 150
4 120 200
5 150 250
12 360 600
Biophan Technologies, Inc. (OTCBB: BIPH)
Sensitivities
Deal Terms Improve with: Proof of principle Issued patents (the more the better) Multiple prospects Cash in the bank Capability Capacity
Biophan Technologies, Inc. (OTCBB: BIPH)
Other Markets
Battery: $500 million Contrast Agents: $800 million Drug Pumps: $1 billion Drug Delivery: $40 billionCautions: Penetration can take timeFDA approval and/or CE Mark could take timeBright side is, once deal is underway, patents and
annuity streams can last a long time
Biophan Technologies, Inc. (OTCBB: BIPH)
Biophan (OTC: BIPH)
We don’t make medical devices; We make them safe, and imageable, for MRI
And other competitive advantages for our customers
Four of our six technologies are based on nanotechnology
WWW.BIOPHAN.COM
Biophan Technologies, Inc. (OTCBB: BIPH)
Thank You!
More good things will unfold in 2005!
BIOmedPHArmaNano
Technologies